CTLA4 and cancer: Immune checkpoint blockade (ICB), which targets programmed cell death ligand 1 (PDL1) and cytotoxic T lymphocyte antigen 4 (CTLA4) pathways, has become a treatment strategy for various types of cancer (Long et al., 2017; Zhang et al., 2021).